Category Archives: Psoriasis

Photo: Courtesy of the Laser & Skin Surgery Center of New York

Dermatologist Robert Anolik treats some of New Yorks most discerning faces his clients include Stephanie Seymour and Kelly Ripa but that doesnt stop him from worrying about fictional characters, too. Over the past few weeks, he, his wife, and their 7- and 5-year-old kids have been watching The Singing Detective, an 80s-era BBC show about a hospitalized mystery writer.

It has great music in it, but my kids keep asking me all these questions about the main character, whos covered in psoriasis and has psoriatic arthritis, says Anolik, a dermatologist at the Laser & Skin Surgery Center of New York. All I can think about is how that patient could be helped dramatically today with the approach of medical dermatology.

Anolik was a protege of the late Dr. Fredric Brandt, who was well-known in the beauty world for popularizing Botox. But what initially drew him to cosmetic dermatology wasnt injections or chemical peels, but DNA, RNA, and proteins. As a molecular biology major at Princeton, he spent one summer at the Institute for Genomic Research, studying the science of sequencing the human genome. In medical school, I saw how protein sequence analysis touched every field in medicine, but particularly skin and aging, he says. I approach skin with that kind of molecular framework to make it healthy and beautiful.

During his dermatological training at NYU, Anolik landed a fellowship with famed dermatologist Roy Geronemus, director of the Laser & Skin Surgery Center. Brandt was also part of the practice, and when he wanted to divide his time more evenly between his Miami and New York practices, Anolik became his official associate.

He wanted someone who also had laser expertise, which he knew I had, says Anolik. Even though we looked like total opposites, our personalities clicked.

Five years later, tragedy struck and Brandt took his own life. Anolik seamlessly took over, with high-profile clients now trusting their complexions to him.

These days, until he can see those patients again, hes been volunteering at Bellevue Medical Center, tending to patients with post-op wounds and other surgery-related issues. Stuff that needs attention by a physician, he says. Theyre all so overwhelmed, so hopefully I can help decrease the burden.

Anolik spoke with the Cut about the calming presence of Angela Lansbury, his complicated relationship with fruit, and why now is the perfect time to exfoliate.

Whats your definition of beauty? The Keats line beauty is truth; truth beauty is a chestnut for a reason. When I look at a face, my goal is to reveal its truth, that is to let its beauty become manifest, which is why I work very hard to eliminate distortions, both external (e.g., sun damage) and internal (e.g., psychological negativity).

What do you think of when you hear the term clean beauty? I get wary when I hear it. I believe in the sentiment that drives the clean beauty concept. As a scientist, however, I also believe in rigorous study over intuition and guesswork. Just because something grows on a tree doesnt mean its safe and/or effective. And even the cleanest ingredients in too high a quantity can be dangerous. For example, drinking too much water will kill us. And, conversely, an ingredient that sounds strange or worrisomely artificial can, in fact, be beneficial. A word of caution for those experimenting with only clean or alternative therapies: If you believe something is strong enough to help you, its likely strong enough to hurt you as well. So dont overdo it! And be sure to consult with a board-certified dermatologist about safe strategies.

Where, if anywhere, in your beauty (or life) routine are you not quitethat clean, green, or sustainable? I drink diet soda. Its dumb and I know better, but I do it anyway.

Please fill in the blank as it pertains to beauty or wellness: I think about ______a lot. SUN DAMAGE.

What is the opposite of beautiful? An artificial appearance. Lips that are too big or faces that are frozen are not beautiful. And believe me, I cringe more than you do when its obvious someone has had work done. Just because we can do something in cosmetic dermatology, doesnt mean we should.

What is your morning skin-care routine? Alastin Gentle Cleanser or Neutrogena Ultra Gentle Cleanser, shave, sulfacetamide wash to reduce shave irritation, LaRoche-Posay Anthelios Melt-In Sunscreen Milk SPF 60, SkinMedica HA5 Rejuvenating Hydrator.

Whats the last product you use every night? A prescription retinoid, then moisturizer. Usually Alastin Ultra-Nourishing Moisturizer or Cerave Cream.

Who cuts your hair? Garren. Asking Garren to cut my hair is like asking van Gogh to paint on a milk carton. But hes my friend; he pretends not to mind.

Toothbrush of choice: My wife bought me a Sonicare but I still use the freebie from the dentist.

Razor of choice: Gilette Fusion 5.

Shaving cream of choice: Gillette Fusion Hydra Shave Gel Ultra-Sensitive.

Hand wash of choice: Dove Foaming Hand Wash.

Hand sanitizer of choice: Purell.

Fragrance of choice: Hermes Eau dorange verte Eau de cologne.

Bath or shower: Shower, with Olay Ultra Moisture Body Wash with Shea Butter, R&Co. Television Shampoo, Television Conditioner, and Acid Wash.

What was your first grooming product obsession? In third grade, I discovered mousse. Id blow-dry my hair with it. Maybe I watched St. Elmos Fire a few too many times.

Daily carry-all of choice: Prada nylon shoulder bag. A gift from Dr. Brandt. Prada was a favorite brand of his.

What do you splurge on? My wifes very particular about our sons footwear. Lots of tiny pairs of Air Jordans, Converse, Vans, and Adidas Gazelles by our front door.

What is your classic uniform (under your lab coat)? Black or navy Brooks Brothers pants and black or navy Ralph Lauren crew neck sweater.

Whose shoes are you usually wearing? Greats Royale sneakers.

What do you own too many of? Medical journals. I know at this point that the past issues are all online where I read the new ones, but theres something enjoyable about referencing them with your handwritten notes. At some point, theyll find their way to the recycling bin.

Any secret talent or skill you possess? I can juggle.

What is your own personal definition of misery? Fruit of any kind in my desserts. I love cake but Im crushed when it turns out to be carrot, and I cannot get enough ice cream but I pout when the flavor turns out to be strawberry.

What is your own personal definition of glee? Getting my cholesterol tested. I dont eat all that well, and Im not great about exercising, but my cholesterol is always low. I find that so gratifying.

Favorite way or place to spend a weekend? Nantucket. My wifes family has a house there, and they make fun of me when I wear my aqua socks to the beach.

What do you most often disagree with others about? People who insist they need to get a base tan before a tropical vacation. This is nuts. You should avoid getting a tan before your tropical vacation and during your tropical vacation and after your tropical vacation. Heres what you should get instead: sunscreen and sun-protective clothing.

What must you adjust or fix when you see it done incorrectly? Bad Botox on someone who comes in for a first-time consultation.

Favorite CBD product: Ridgway Hemp Love Balms.

What calms you down? Seinfeld reruns on Netflix. And when Im really feeling stressed: Murder, She Wrote reruns on Amazon Prime (dont judge).

Comfort food: Oreos and milk.

Vice snack: Chili-roasted pistachios and Empire Bakery house-made Twinkies.

What do you foresee as the top beauty and wellness trends for 2020? Combination therapy, specifically more one-day treatments that combine multiple lasers and injections. We have been developing this for years and are now presenting safety data on the subject.Also, laser-assisted drug therapy, such as resurfacing lasers followed by topical applications of skin-brightener serums and platelet-rich plasma. Heres what I hope is the top beauty/wellness trend in 2020: a public repudiation of non-board-certified dermatologists performing cosmetic dermatology procedures on people.

What treatment at your practice is misunderstood and should be morepopular? Laser resurfacing. Granted, this is already a very popular treatment in our office, but I believe it should be even more popular. Somepatients come in with misinformation that laser resurfacing thins theskin. Nothing could be further from the truth. In fact, it does theopposite. It targets collagen-producing cells in the dermis andgenerates a stronger, more resilient skin.

What treatment is currently your favorite (understanding that thiscould change all the time)? Botox. And it has been for years. Precise treatment avoids artificial outcomes and allows for a refined, rejuvenated, lifted, rested appearance.

What activity do you do when the stress becomes too much these days?Cook. Ive been spending a lot of time with my cast-iron skillet. My cast-iron pizza is a favorite.

What have you been binge-watching? Ozark season three for suspense how good is Tom Pelphrey as Laura Linneys brother? And Cheers for laughs.

What has been an upside to this crazy time for you? My time with my wife and young sons, except during the screaming. And the homeschooling. And the cleaning.

Whats a good beauty treatment for someone whos stuck at home? Exfoliation. A downside of exfoliation is it can sometimes leave the skin dry and flaky, but if youre staying home, thats okay!

Conversely, what in your own grooming routine are you less on top of these days?Shaving, although my wife prefers a cleaner look, so early signs of a beard appear only now and then.

When this is all over, what are the first three to five things youll do or places youll go? The office will be my first stop! I miss my amazing patients! I expect Ill be there in overtime mode for a while getting everyone in. Id love a flat white at Laughing Man in Tribeca, maybe a burger at Odeon. Also we watched King Kong with the kids during quarantine, so my oldest wants me to take him to the top of the Empire State Building. He thinks King Kongs going to be there. I havent had the heart to set him straight.

Get the Cut newsletter delivered daily

The rest is here:
The Dermatologist Whos Obsessed With Sun Damage - The Cut

People with psoriasis may be wondering how COVID-19 might affect them. COVID-19 is a new illness resulting from infection with the novel coronavirus, or SARS-CoV-2.

At present, it is unclear how COVID-19 may affect those with psoriasis, which is an immune-mediated condition. This mean the condition occurs as a result of abnormal immune system activity. Scientists are also unsure about how it may impact the treatment of these individuals.

Some treatments for psoriasis, which are immunosuppressive medications, may increase the risk of a COVID-19, or of severe illness due to the virus. However, the effects are still unknown.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

Keep reading to learn more about the potential risks of COVID-19 for those with psoriasis, including the precautions that people can take to reduce their risk of developing COVID-19 and its complications.

The details of how COVID-19 affects those with psoriasis remain unknown, but there is not yet evidence to suggest that it affects them differently than people without the condition.

According to the National Psoriasis Foundation (NPF), if a person is not taking an immunosuppressive medication and is free from other underlying diseases, there may be minimal additional risk of them contracting SARS-CoV-2 relative to the rest of the population.

However, as the virus is highly transmissible, spreads rapidly, and replicates rapidly, everyone is at risk. Even asymptomatic people can transmit the virus to others.

The NPF note that people with severe psoriasis, such as those who are on immunosuppressive therapies or have other medical conditions, probably are at higher risk of infection.

As psoriasis is a chronic immune-mediated condition, some people may take immunosuppressant drugs to keep their symptoms under control.

These medications can reduce immune function, which may increase the risk of infection with SARS-CoV-2 or other infectious agents. Immunosuppressive drugs could also increase the risk of severe symptoms.

According to the Centers for Disease Control and Prevention (CDC), conditions or medications that weaken the immune system and cause people to become immunocompromised increase the risk of severe COVID-19.

The International Psoriasis Council (IPC) recommend that people with psoriasis who receive a COVID-19 diagnosis discuss discontinuing or postponing their use of immunosuppressant medications with their doctor.

However, the IPC caution that doctors should carefully weigh the benefit-to-risk ratio of immunosuppressive treatments on an individual basis.

The medical board of the NPF do not recommend that people with psoriasis stop their treatment unless they have an active infection. They suggest that those in high risk groups discuss their options with their doctor.

The CDC list the following as high risk:

The World Health Organization (WHO) and other expert bodies are still learning about the effects of COVID-19 on those with co-occurring conditions.

The WHO list the most common COVID-19 symptoms as:

They state that other possible symptoms include:

Some people with COVID-19 also report a loss of taste or smell.

Symptoms typically develop within 214 days of exposure to the virus. They range from mild to severe, although the majority of people experience a relatively mild form of the disease, which will not require specialist treatment in a hospital.

Some people may be asymptomatic, meaning that they have no symptoms, despite testing positive for the virus that causes COVID-19. Asymptomatic individuals can still transmit the virus to others, though.

People can reduce the risk of exposure to the novel coronavirus by:

Anyone who thinks that they may have become exposed to the virus should:

It is advisable to call ahead before presenting at an emergency facility in case they need to put safety measures in place.

The NPF recommend that people with psoriasis discuss their treatment with their doctor. A doctor may recommend continuing medications or taking a break from them.

It is important that people only adjust or stop their treatment after consulting with their doctor.

So far, there is no specific treatment or vaccine for COVID-19. In those who contract the virus and develop symptoms, treatment aims to alleviate these symptoms. Treatments include:

People who develop severe illness will require hospitalization. In the hospital, doctors may put them on oxygen or a ventilator, or provide other specialist care.

In some cases, doctors may speak to a person about participating in a clinical trial, which is very important in helping experts learn about the disease and find effective treatments.

People with psoriasis who develop COVID-19 should speak to their doctor about their psoriasis treatment while ill.

Those taking immunosuppressive medications will often need to stop treatment temporarily until their doctor says that it is safe to resume. The doctor will advise on other types of psoriasis treatment on a case-by-case basis.

When someone tests positive for the novel coronavirus, their doctor will provide them with instructions for recovery. They will also explain to the individual how to self-isolate to reduce the spread of the virus to others.

People with mild symptoms can typically recover at home, while those with severe illness often require a hospital stay.

It is difficult to determine the outlook for people with COVID-19 and psoriasis, but this generally depends on:

Data from China showed that 80% of people who develop COVID-19 have mild-to-moderate symptoms and recover well. Of the remainder, 13.8% develop severe disease, and 6.1% become critical and require intensive care.

Prompt medical treatment may improve the outlook of people with severe disease and reduce the risk of complications, which include pneumonia and organ failure. In some cases, COVID-19 can also lead to death.

At present, experts know little about the effects of COVID-19 on people with psoriasis.

However, it seems that those who are not taking an immunosuppressive medication and do not have another co-occurring disorder have a similar risk to the rest of the population.

People taking immunosuppressive therapies who receive a COVID-19 diagnosis should consult their doctor immediately. It is likely that the doctor will advise them to stop taking these medications until they recover.

There is no specific treatment for the novel coronavirus, but individuals can reduce their risk of contracting it by maintaining physical distance from others, avoiding unnecessary public outings, and practicing good hygiene.

Individuals with psoriasis should speak to their doctor about their specific case. A doctor will address any concerns that a person has, and they may adjust their treatment plan accordingly.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See the rest here:
COVID-19 and psoriasis: Risks and precautions - Medical News Today

The feasibility and efficacy of a joint dermatology-rheumatology clinic for the treatment of patients with psoriasis (PsO) and psoriatic arthritis (PsA) is supported by study data published in Dermatological Therapies.

Established at Attikon General University Hospital in Athens, Greece, the Psoriasis and Psoriatic Arthritis Clinic (PPAC) integrates expertise from dermatologists and rheumatologists for the treatment of patients with psoriasis and psoriatic arthritis. The dual clinic is held once a week by 6 specialists; the same hospital also holds regular psoriasis clinics twice weekly. On average, the PPAC receives 40 new patients per month. Patients typically belong to 2 categories: patients with psoriasis who are suspected to also have psoriatic arthritis, and patients with a rheumatology diagnosis in whom psoriatic arthritis is suspected. Demographic and clinical characteristics were extracted from patients who attended the clinic from 2017 to 2018. In addition, patient satisfaction with PPAC care was assessed using a Visual Analogue Scale (VAS).

The PPAC saw 185 patients with psoriasis who were diagnosed with psoriatic arthritis from December 2018 to January 2019. In these patients, mean age of psoriasis onset was 34 16 years and mean age of psoriatic arthritis onset was 47 12 years. The majority of patients had a diagnosis of severe plaque psorisis (78%). The most commonly diagnosed psoriatic arthritis was asymmetric oligoarticular arthritis (32%). More than half of patients were receiving biologic agents (57%) as treatment for psoriasis and psoriatic arthritis. Comorbidity rates were high, with 40% and 37% reporting hypertension and dyslipidemia, respectively.

In addition, 9% and 11% were being monitored for diabetes and depression, respectively. Patients reported high levels of satisfaction with the PPAC facility compared with attending separate clinics on referrals. The mean satisfaction-VAS score was 8611.5. Patients typically endorsed that the PPAC was timely, efficient, and patient-centered. Most patients also agreed that collaboration and teamwork between dermatologists and rheumatologists was essential to their care. When surveyed, dermatologists in the PPAC also agreed that interprofessional collaboration improved patient care quality and clinical outcomes.

These data support the feasibility of dual dermatology-rheumatology clinics for the management of psoriasis and psoriatic arthritis, study authors assert. Investigators noted that a strong word of mouth impact was observed from the PPAC, with many patients recommending the clinic to spouses or other family members. From a single clinical site and a relatively small cohort, results may not be generally applicable to other patient populations. Despite this, data support the concept of combined clinics delivering better integrated care forpatients [with PsO and PsA], the authors concluded.

Reference

Theodorakopoulou E, Dalamaga M, Katsimbri P, Boumpas DT, Papadavid E. How does the joint dermatology-rheumatology clinic benefit both patients and dermatologists? [published online February 24, 2020]. Dermatol Ther. doi: 10.1111/dth.13283

This article originally appeared on Dermatology Advisor

See original here:
Dermatology-Rheumatology Care Clinic Reports High Satisfaction From Patients With Psoriasis, Psoriatic Arthritis - Rheumatology Advisor

BACKGROUND:

Plaquepsoriasiscan occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion demonstrated efficacy and safety in patients with moderate-to-severe localized plaquepsoriasis. This analysis evaluated patients where a psoriatic target lesion was identified on the leg.

In two phase 3, multicenter, double-blind studies, participants were randomized (2:1) to receive HP/TAZ or vehicle lotion once-daily for 8 weeks. This pooled, post hoc analysis included a subset of participants who had a leg target lesion (HP/TAZ, n=148; vehicle, n=71). Efficacy assessments included treatment success (2-grade improvement) inpsoriasissigns (erythema, plaque elevation, scaling) on the leg target lesion, and overall treatment outcomes, including overall treatment success (2-grade improvement in Investigators Global Assessment [IGA] score and score of clear/almost clear), affected Body Surface Area (BSA), and IGAxBSA composite score.

Psoriasissigns were reduced by week 8, with more HP/TAZ treated participants achieving treatment success for erythema (41.6%), plaque elevation (58.5%), and scaling (59.5%) on the leg compared with vehicle (12.5%, 19.2%, and 21.0%, respectively; P<0.001 all). Significantly more participants achieved overall treatment success at week 8 with HP/TAZ versus vehicle (36.4% vs 10.4%; P<0.001). The HP/TAZ group also had a greater mean reduction in affected BSA and IGAxBSA score versus vehicle (P<0.001, both). The most frequently reported treatment-related adverse event (incidence, 3%) with HP/TAZ was contact dermatitis.

HP 0.01%/TAZ 0.045% lotion was associated with significant reductions in disease severity and good tolerability following 8 weeks of treatment in patients where a psoriatic target lesion was identified on the leg. J Drugs Dermatol. 2020;19(4):389-396. doi:10.36849/JDD.2020.4958.

See the article here:
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities - DocWire News

OBJECTIVE:

Sleep quality is diminished in patients with psoriaticarthritis(PsA) and close to 40% of PsA patients consider sleep difficulties a priority domain. This work analyzes determinants of impaired sleep in patients with PsA.

This was a cross-sectional analysis of an observational study (ReFlap, NCTNCT03119805), which included adult patients with definite PsA with 2 years disease duration from 14 countries. Sleep was assessed using the patient self-reported evaluation of sleep on a 0-10 numerical scale, included in the PsoriaticArthritisImpact of Disease questionnaire (PSAID-12). A score 4 was considered as sleep impairment. Demographic and clinical variables associated to sleep impairment were assessed through univariate analysis and Poisson regression modeling leading to prevalence ratio (PR) [95% confidence interval].

A total of 396 patients were analyzed: mean age 51.912.6 years, 51% were females, 59.7% were receiving biologic therapy, 53.3% had 1-5% of body surface area affected by psoriasis; 23.7% were in remission and 36.9% in low disease activity according to the Disease Activity in PsoriaticArthritis(DAPSA) score. Median (25th-75th) patients self-evaluation of sleep difficulties was 2 (0-6), 157 (39.6%) had sleep impairment. In the Poisson regression model, self-reported levels of anxiety (PR: 1.05 [1.02-1.08], p=0.003) and pain (PR: 1.06 [1.04-1.09], p<0.001) were independently associated to sleep impairment.

In this multicentric study, sleep impairment was present in 40% of PsA patients; pain and anxiety were associated to sleep impairment whereas inflammation was not. Impact on sleep appears multifactorial in PsA.

Read the original post:
Determinants of sleep impairment in psoriatic arthritis: an observational study with 396 patients from 14 countries - DocWire News

Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.

Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty payments in the mid- to high-single digits.

Sitryx grants Lilly exclusive, worldwide license to develop and commercialize up to four immunometabolism targeted compounds, including Sitryxs two lead projects. The partnership will run for five years, with Sitryx taking on drug discovery and Lilly paying for and handling clinical development and commercialization.

As Lilly seeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners, said Ajay Nirula, vice president of immunology at Lilly. Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets.

Sitryx was founded in 2018 with seed funding from SV Health Investors and by six researchers in immunology and immuno-regulation: Houman Ashrafian (SV Health Investors), Luke ONeill (Trinity College Dublin), Jonathan Powell (Johns Hopkins), Jeff Rathmell (Vanderbilt University), Michael Rosenblum (University of California San Francisco) and Paul Peter Tak (formerly chief immunology officer, global development leader and senior vice president R&D Pipeline at GlaxoSmithKline; Amsterdam University Medical Centre). It raised $30 million in Series A funding from SV Health Investors, Sofinnova Partners, Longwood Fund and GlaxoSmithKline in 2018.

The scientific focus of the company is regulating cell metabolism to treat diseases.

We are excited to partner with Lilly, one of the global leaders in the field of immunology, to pursue the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory diseases in the fast-emerging area of immunometabolism, said Neil Weir, chief executive officer of Sitryx. This agreement is transformational for Sitryx and further validates the strength of our scientific expertise and that of our Founder network and the potential for Sitryx to become a leader in this field.

Yesterday, Lilly announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) for the treatment of children ages six to 18 with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The application was based on a Phase III trial of 171 patients with moderate to severe plaque psoriasis. The trial had co-primary endpoints, including the proportion of patients hitting a 75% improvement on their Psoriasis Area and Severity Index Score (PASI 75) and a static Physicians Global Assessment of clear or almost clear skin at Week 12.

Due to limited pediatric psoriasis treatment options available, treating children and adolescents with moderate to severe plaque psoriasis can be challenging, said Stacie Bell, chief scientific and medical officer, National Psoriasis Foundation. Having more FDA approved pediatric psoriasis treatment options available is a positive step forward in helping relieve the burden of psoriasis for pediatric patients, their families and the health care providers that treat these young patients.

Read the original here:
Lilly and Sitryx Sign $880 Million+ 5-Year Development Deal - BioSpace

Compared with control participants, patients with psoriatic arthritis (PsA) display a significantly greater expression of 6 serum microRNAs (miRNAs), according to study results published in Journal of Rheumatology.1 In addition, baseline expression of certain serum miRNAs was associated with treatment response in patients with PsA.

Prior research has suggested that miRNA, small, noncoding RNA molecules, may serve as regulators in the pathogenesis of autoimmune diseases.2 The researchers sought to explore the relationship between serum miRNA levels and PsA.

Patients with PsA (n=31) were enrolled from outpatient rheumatology clinics at St Vincents University Hospital in Dublin, Ireland. All patients underwent baseline clinical and laboratory assessments, including quantification of C-reactive protein (CRP) levels and erythrocyte sedimentation rates (ESR). Follow-up visits were conducted at 3, 6, and 9 months after PsA treatment initiation. Patients were classified as either treatment responders or nonresponders according to the European League Against Rheumatism criteria. A cohort of healthy control participants (n=20) was enrolled from the community. All study participants underwent a peripheral blood draw; a focused immunology panel of 68 miRNAs of interest was analyzed for each serum sample. The miRNA that were differentially expressed between the 2 study groups were selected for further analysis. Area under the receiver operating characteristic curve (ROC) was used to assess the predictive capacity of each miRNA.

Of the identified miRNAs, 6 were significantly overexpressed in patients with PsA compared with control participants; the 6 miRNAs included miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p (all P <.001), and miR-21-5p (P <.01). According to ROC analyses, miR-130a-3p and miR-26a-5p emerged as the strongest predictors of PsA vs healthy control participants, with area under the curve values of 0.866 and 0.894, respectively. When miRNA expression was compared with nonspecific markers of inflammation, including ESR and CRP, only miR-130a-3p (r=0.53; P =.004) and miR-146a-5p (r=0.41; P =.03) correlated with CRP.

In addition, no significant associations were observed between miRNAs and ESR, suggesting that the 6-miRNA signature was PsA-specific and not just a marker of inflammatory disease. In prospective analyses, greater baseline expression of miR-130a-3p (P <.01), miR-221-3p, miR-146a-5p, miR-151a-5p, and miR-26a-5p (all P <.05) was associated with PsA therapeutic response vs nonresponse. Expression profiles did not appear to differ between patients receiving biologic vs nonbiologic therapies. The ROC analysis identified miR-221-3p, miR-130-3p, and miR-146a-3p as the strongest predictors of therapeutic response, with AUC values of 0.747, 0.760, and 0.717 respectively.

The results describe a serum microRNA signature with high discriminative capacity between PsA and control participants, as well as moderate prognostic capacity for PsA treatment response. Further study of these biomarkers is necessary to elucidate the pathogenesis of PsA.

References

1. Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ. Serum microRNA signature as a diagnostic and therapeutic marker in patients in patients with psoriatic arthritis [published online March 1, 2020]. J Rheumatol. doi:10.3899/jrheum.190602

2. Pauley KM, Cha S, Chan EKL. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3-4):189-194.

Follow this link:
MicroRNA Signature May Predict Diagnosis and Treatment Response in Patients with PsA - Rheumatology Advisor

The skin is the bodys largest organismit is its defense against the worldso it makes sense that the immune system is very active in the skin, Tina Bhutani, M.D., M.A.S., a dermatologist and codirector of the University of California San Francisco (UCSF) Psoriasis and Skin Treatment Center and of the UCSF Dermatology Clinical Research Unit, tells SELF. But, she adds, researchers arent sure why some people get psoriasis and others dont.

We know patients have a genetic predisposition, but in addition, theres something environmental that happens to trigger their psoriasis, Dr. Bhutani explains. In some, that might be an infection, in others that might be some kind of stressor, like a psychological or physical stress on the body.

Research has shown that psoriasis can contribute to or worsen various mental health conditions, including depression, anxiety, bipolar disorder, eating disorders, and more. If you have psoriasis, you might be intimately familiar with how this worksespecially right now, given that basically all of us are feeling mental strain in unprecedented ways thanks to the new coronavirus.

While its a bit of a chicken-and-egg situation, Dr. Bhutani says that mental health conditions like anxiety or depression may kickstart the onset of psoriasis or trigger and exacerbate flare-ups. Beyond that, There are studies showing that major stressful life events, such as a death in the family, can result in the new onset of psoriasis, Joel Gelfand, M.D., MSCE (Master of Science in Clinical Epidemiology), professor of dermatology and epidemiology and director of the Psoriasis and Phototherapy Treatment Center at the Perelman School of Medicine at the University of Pennsylvania, tells SELF.

On the other hand is the fact that having psoriasis may contribute to you developing a mental health condition (or make it worse). There are studies that show patients with psoriasis are more likely to develop issues such as anxiety and depression over time, Dr. Gelfand says.

Anyone who has worried about not fitting in with narrow definitions of beauty can understand how having a visible skin condition could take a toll on someones mental health. One can imagine how the physical [stigma] of psoriasisespecially when plaques affect exposed areas of the skincan affect mood and interpersonal interactions in a negative way, Evan Rieder, M.D., an assistant professor of dermatology at NYU Langone who is board-certified in both psychiatry and dermatology, tells SELF. These can happen both through how someone with psoriasis views [themselves], but also through the reactions of others to their skin.

Like many people with psoriasis, Jennifer Pellegrin, 36, knows all too well how the condition can impact a persons social life and mental health. She was diagnosed with psoriasis when she was 15 and with psoriatic arthritis at 25, followed by depression a year later and then anxiety. Psoriasis causes an exacerbation of my [mental health conditions], she tells SELF in an email. I go through days sometimes where I cancel all plans. I can be looking forward to going out, start to get ready, and boom: Anxiety hits. I feel hideous and wont leave the house.

In addition to the more obvious ways psoriasis and mental health can play off each other, experts have done a fair amount of research into the biological mechanisms that may connect psoriasis and various mental health conditions. A 2016 systematic review in the Journal of Clinical and Aesthetic Dermatology looked at 57 studies on the subject, noting that psychological stress and depression can boost the release of pro-inflammatory cytokines, which are molecules released as part of the immune response. The inflammation they cause seems capable of further exacerbating the symptoms of both psoriasis and conditions like depression. However, theres conflicting research on this; some of the literature hasnt found definitive associations between psoriasis and psychological issues like stress.

Read more:
The Vicious Cycle Between Psoriasis and Mental Health - Self

HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursement lists. The Company has also been on track to advancing R&D pipelines, and stepping up efforts to introduce innovative therapies for cancer and autoimmune diseases into global markets. In the future, 3SBio will further boost its advantages with a comprehensive platform that integrates R&D, manufacturing, commercializationand investment cooperation, while consolidating and improving its status as a leading biopharmaceutical company.

Realizing sound business performance; sales of TPIAO exceeding RMB 2 billion

In 2019, 3SBio's revenue rose by 16.0% year on year to approximately RMB 5.318 billion. Gross profit increased by 18.5% to approximately RMB 4.393 billion. Normalized net profit attributable to owners of the parent added by 19.4% to approximately RMB13.92 billion.

The Company's four core products, including TPIAO, Yisaipu, EPIAO and SEPO, remained market leaders in China. Sales of TPIAO, which is the world's only commercialized recombinant human thrombopoietin ("rhTPO"), for the treatment of thrombocytopenia, soared 39.1% to exceed RMB 2 billion, with its market share jumping to 73.2%. Yisaipu, a product to treat rheumatoid arthritis , ankylosing spondylitis and psoriasis, had a market share of 60.9%. Two recombinant human erythropoietin ("rhEPO") products, EPIAO and SEPO, maintained market-leading positions, with their market share improving to 41.6%. As there is huge unmet demand for biologics in China, TPIAO and Yisaipu, which have low penetration rates, will see significant growth potential in the future.

Several of the Company's products and indications have been added into the updated 2019 National Reimbursement Drug List (NRDL), including Shinuo, a fluticasone propionate cream for the treatment of multiple skin diseases, the new indication of Yisaipu for the treatment of adult patients with severe plaque psoriasis, and the new indication for EPIAO for the treatment of anemia caused by chemotherapy for non-myeloid malignant tumors. Humulin, a mixed protamine zinc recombinant human insulin injection, was upgraded to Class A from Class B in the NRDL. Byetta, a therapy for the treatment of patients with type 2 diabetes, was added into the NRDL through negotiations.

Also, Xenopax, the first approved recombinant humanized anti-CD25 monoclonal antibody injection in China, was granted the Chinese GMP certificate and launched in the market in October, 2019.

R&D expenses up 45.2%, with follow-up pipelines on 'fast track'

In 2019, 3SBio's R&D expenses soared by 45.2% to approximately RMB 527 million. The Company has its best-ever pipeline of biological cancer therapies, including anti-HER2, CD20, PD1, EGFR and VEGF antibodies. The Company's pipeline of biological therapies for the treatment of autoimmune and inflammatory diseases, including anti-TNFa, IL-17A and IL-5 antibodies, has all made significant progress.

302H (Inetetamab), an anti-HER2 monoclonal antibody drug, has completed the technical review, clinical trial site inspection as well as manufacturing site inspection. An application for manufacturing approval of pre-filled aqueous injection solution of Yisaipu has been filed and accepted by the National Medical Products Administration, and it is currently under the review process.

In 2019, the Company's drug candidates received five IND approvals, including: anti-PD1 antibody for the treatment of various cancers (simultaneous applications in China and the US); anti-IL-17A antibody for the treatment of moderate to severe plaque psoriasis; TRK820 (Remitch) for the treatment of pruritus in hemodialysis patients; and HIF-117 capsules for the treatment of anemia. In February 2020, the Company's anti-IL-5 antibody for the treatment of asthma was approved for a clinical trial.

The Company has also been proactively expanding new indications and second-generation products of existing products, including NuPIAO, a second-generation rhEPO; RD001, a pegylated long-acting rhEPO; and the pediatric ITP indication of TPIAO.

Story continues

Also, the Company selected Verseau Therapeutics Inc's VTX-0811, a monoclonal antibody targeting PSGL-1 for the treatment of multiple types of cancer, as the first licensed program under the partnership in the field of immuno-oncology.

3SBio's R&D highlights in 2019

3SBios R&D highlights in 2019

As of December 31, 2019, amongst the 32 product candidates within the Company's active pipeline, 22 were being developed as National New Drugs in China (including registration Class I and Biologics Class II), including 11 in oncology, 12 in autoimmune and other diseases, 6 in nephrology, 2 in metabolic diseases and 1 in dermatology.

Expanding global presence in therapies for cancer and autoimmune diseases

In 2019, 3SBio was continuously expanding external partnerships and global presence for its innovative therapies in the fields of cancer and autoimmune diseases, including the partnership with global biologics giant Samsung Bioepis in South Korea for the development of biosimilar candidates; collaboration with Verseau Therapeutics in the United States for global clinical development of macrophage checkpoint modulators; partnership with Taiwan Liposome Company for the development of innovative liposomal products; and collaboration with Numab to develop new multispecific antibodies for cancer immunotherapy. The Company also invested GenSight and Sensorion to explore innovative gene therapies for ophthalmic diseases and innovative treatments for inner ear diseases.

In early 2020, the Company became a limited partner in the MPM Oncology Innovations Fund (INV), and agreed to make donation to support early-stage oncology research at Dana-Farber Cancer Institute, a world-leading cancer research and treatment center.

These collaborations demonstrated 3SBio's excellent expertise in international development and operation, while laying a key stepping stone for its future globalization strategy. The Company will continue to pursue selective mergers and acquisitions and collaboration opportunities and explore cutting-edge innovative therapies in early stages, with an aim to enrich its existing product portfolio and become a leader in next-generation immuno-oncology therapies.

Comprehensive platform with strong competitive advantages

In the future, 3SBio intends to reinforce its position as a leading biopharmaceutical company in China by continuously leveraging its integrated R&D, manufacturing, commercializationand investment cooperation platforms. The Company will also focus on developing innovative biologics products to address unmet medical needs to benefit more patients.

The Company will fully integrate the R&D teams of nearly 400 people on multiple R&D platforms, and actively develop innovative therapies including monoclonal antibodies, bispecific antibodies, antibody fusion proteins, and cell therapies, thereby bringing a variety of treatment options to patients. The Company will kick off multiple phase III clinical trials this year, file new drug applications for more than 10 products in the next 3 years, and also submit IND applications for10-15 new monoclonal antibodies and bispecific antibodies (simultaneous applications in China and the US).

The Company has approximately 38,000-liter capacity in mAb facility, mammalian cell-based, bacteria cell-based and small molecule manufacturing facilities, and more than 27 years of experience in manufacturing biologics medicines. With large-scale production capacity that meets international quality standards, the Company is able to continuously supply the market with high-quality biologics. Over nearly 3 decades, the Company has been well recognized for its strong commercial operation capabilities and sales network throughout the country, which supports its sustainable growth.

Dr. Jing LOU, Chairman and CEO of 3SBio, commented: "Under the backdrop of the COVID-19 pandemic globally, 3SBio supports the country in our own way, through thick and thin. As we face a market environment where opportunities and challenges coexist, 3SBio is still maintaining strong growth momentum by leveraging our well-established systems that we've developed over the years. we will strive to overcome all difficulties, accelerate clinical applications and progress for our pipeline. We will also expand our production capacity and give full play to the advantages of our integrated platform. We aim to become a globally leading Chinese biopharmaceutical company, and continuously improve the availability of innovative biologics to benefit more patients."

View original content to download multimedia:http://www.prnewswire.com/news-releases/3sbio-unveils-2019-annual-results-revenue-rises-by-16-0-normalized-net-profit-attributable-to-owners-of-the-parent-jumps-by19-4-rd-expenses-soar-45-2-301032239.html

SOURCE 3SBio Inc.

Go here to read the rest:
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar...

Global Psoriasis Treatment Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 9.3 % during forecast period of 2019 to 2026.

Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin growth, skin patches are typically red, dry, itchy, and scaly.

Global Psoriasis Treatment Market Drivers and Restrain

Rising prevalence of the condition, heading with growing awareness, the screening and diagnosis of the disease are expected to fuel the global psoriasis treatment market in the coming years. Psoriasis treatment options also contribute to a number of side-effects such as liver and kidney damage, hypertension, and increased risk of cancer, etc., are the factors could hamper the growth of Global Psoriasis Treatment Market in forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/37175

Global Psoriasis Treatment Market key segmentation

By drug class, the global market has been categorized into TNF inhibitors, Interleukin inhibitors, Vitamin D analogs, Corticosteroids, and others. Tumour Necrosis Factor Inhibitors is further categorized as Adalimumab, Infliximab, Etanercept. Vitamin D Analogues is segmented into Calcitriol, Calcipotriol, Tacalcitol. The Interleukin inhibitors segment is projected to lead the global psoriasis treatment market during the forecast period.

High market share of the interleukin inhibitors segment can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Moreover, the acceptance of this drug class is attributable to interleukin blockers, which are considered to be a viable option for patients having trouble responding to other treatment.

Global Psoriasis Treatment Market Regional Analysis

By region, the global psoriasis market to witness dominance of North America followed by Europe. As per the National Psoriasis Foundation, there are about X million people in America living with psoriasis. Because of quick adoption of biological therapy and rise in investments on research and development for clinical trials will drive global market in this region. On the other side, the emerging markets in the Middle East and Africa, Latin America, and Asia Pacific are expected to offer growth opportunities thanks to increasing patient pool, the improving healthcare infrastructure and medical facilities.

The objective of the report is to present comprehensive analysis of Global Psoriasis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Psoriasis Treatment Market dynamics, structure by analyzing the market segments, and project the Global Psoriasis Treatment Market size. Clear representation of competitive analysis of key players by Psoriasis Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Psoriasis Treatment Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/37175

Scope of the Global Psoriasis Treatment Market

Global Psoriasis Treatment Market Drug class

Corticosteroids Tumour Necrosis Factor Inhibitors interleukin inhibitors Vitamin D AnaloguesGlobal Psoriasis Treatment Market by Treatment

Biologic Drugs Small Molecule Systemic Drugs Tropical TherapiesGlobal Psoriasis Treatment Market by Route of administration

Oral Parenteral TopicalGlobal Psoriasis Treatment Market by region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating on Global Psoriasis Treatment Market

AbbVie Inc., Amgen Inc., AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Stiefel Laboratories Inc. (GlaxoSmithKline plc.), Sun Pharmaceutical Industries

MAJOR TOC OF THE REPORT

Chapter One: Psoriasis Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Psoriasis Treatment Market Competition, by Players

Chapter Four: Global Psoriasis Treatment Market Size by Regions

Chapter Five: North America Psoriasis Treatment Revenue by Countries

Chapter Six: Europe Psoriasis Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Psoriasis Treatment Revenue by Countries

Chapter Eight: South America Psoriasis Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Psoriasis Treatment by Countries

Chapter Ten: Global Psoriasis Treatment Market Segment by Type

Chapter Eleven: Global Psoriasis Treatment Market Segment by Application

Chapter Twelve: Global Psoriasis Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Psoriasis Treatment Market Report at: https://www.maximizemarketresearch.com/market-report/global-psoriasis-treatment-market/37175/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Continue reading here:
Global Psoriasis Treatment Market Industry Analysis and forecast (2019 to 2026) - Stock Market Herald